Heidi A. Lane

18.1k total citations · 6 hit papers
113 papers, 14.6k citations indexed

About

Heidi A. Lane is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Heidi A. Lane has authored 113 papers receiving a total of 14.6k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Molecular Biology, 51 papers in Oncology and 37 papers in Cell Biology. Recurrent topics in Heidi A. Lane's work include Microtubule and mitosis dynamics (34 papers), PI3K/AKT/mTOR signaling in cancer (32 papers) and Cancer Treatment and Pharmacology (22 papers). Heidi A. Lane is often cited by papers focused on Microtubule and mitosis dynamics (34 papers), PI3K/AKT/mTOR signaling in cancer (32 papers) and Cancer Treatment and Pharmacology (22 papers). Heidi A. Lane collaborates with scholars based in Switzerland, United States and United Kingdom. Heidi A. Lane's co-authors include Nancy E. Hynes, Erich A. Nigg, José Baselga, George Thomas, Qing‐Bai She, Francesco Hofmann, Gordon B. Mills, Neal Rosen, Daniel J. Hicklin and Kathryn O’Reilly and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Heidi A. Lane

109 papers receiving 14.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ERBB receptors and cancer: the complexity of targeted inhibitors

2005 2.6k citations Nancy E. Hynes, Heidi A. Lane Nature reviews. Cancer profile →
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

2006 2.0k citations Kathryn O’Reilly, Qing‐Bai She et al. Cancer Research profile →
Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo

1995 787 citations Heidi A. Lane, Erich A. Nigg et al. profile →
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

2004 781 citations Heidi A. Lane et al. profile →
Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes.

1996 591 citations Heidi A. Lane, Erich A. Nigg profile →
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

2009 504 citations José Baselga, Michael Stumm et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Heidi A. Lane

Since Specialization

Citations

This map shows the geographic impact of Heidi A. Lane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidi A. Lane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidi A. Lane more than expected).

Fields of papers citing papers by Heidi A. Lane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heidi A. Lane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidi A. Lane. The network helps show where Heidi A. Lane may publish in the future.

Co-authorship network of co-authors of Heidi A. Lane

This figure shows the co-authorship network connecting the top 25 collaborators of Heidi A. Lane. A scholar is included among the top collaborators of Heidi A. Lane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heidi A. Lane. Heidi A. Lane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination 2024 ·Frontiers in Oncology ·(unknown), Nicole Forster, Felix Bachmann, (unknown), Paul M.J. McSheehy, (unknown), (unknown), Anna C. Groner, Mila Roceri, (unknown), (unknown), Nicole Willemsen‐Seegers, Jos de Man, (unknown), (unknown), Guido J.R. Zaman, Rogier C. Buijsman, Laurenz Kellenberger, Heidi A. Lane	1
2	Lisavanbulin in patients with recurrent glioblastoma: Phase 2a results and a consolidated analysis of response-predictive biomarkers. 2023 ·Journal of Clinical Oncology ·Juanita Lopez, Simon Haefliger, Ruth Plummer, Paul M. Clément, Heinz Läubli, Patrick Roth, T.R. Jeffry Evans, Lucy Brazil, Ghazaleh Tabatabai, Antje Wick, (unknown), Benjamin Wunderlich, (unknown), Joel R. Eisner, Marc Engelhardt, Thomas Kaindl, Heidi A. Lane, Peter Hau, Thomas Hundsberger, Joachim P. Steinbach	1
3	382P The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: Final results from a phase I study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma (GBM) 2020 ·Annals of Oncology ·(unknown), Alexandar Tzankov, Ruth Plummer, (unknown), Igor Vivanco, Paul Mulholland, Bora Gürel, I. Figueiredo, (unknown), Stephanie Anderson, Felix Bachmann, Marc Engelhardt, Thomas Kaindl, Heidi A. Lane, (unknown), (unknown), Sabina Berezowska, JEFF EVANS, Rebecca Kristeleit, Juanita Lopez	2
4	The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells 2016 ·Molecular Cancer Therapeutics ·Raphaël Bergès, Aurélie Tchoghandjian, Stéphane Honoré, Marie‐Anne Estève, Dominique Figarella‐Branger, Felix Bachmann, Heidi A. Lane, Diane Braguer	21
5	Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition 2009 ·Molecular Cancer Therapeutics ·Madlaina Breuleux, (unknown), Christine Stephan, Cheryl A. Doughty, Louise Barys, Saveur-Michel Maira, David J. Kwiatkowski, Heidi A. Lane	181
6	mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor 2009 ·Clinical Cancer Research ·Heidi A. Lane, Jeanette M. Wood, Paul M.J. McSheehy, Peter R. Allegrini, Anne Boulay, Joseph Brueggen, Amanda Littlewood‐Evans, Sauveur-Michel Maira, Georg Martiny‐Baron, Christian Schnell, Patrizia Sini, Terence O’Reilly	196
7	AKT/mTOR Pathway Activation and BCL-2 Family Proteins Modulate the Sensitivity of Human Small Cell Lung Cancer Cells to RAD001 2009 ·Clinical Cancer Research ·Marin Marinov, Algirdas Ziogas, Olivier E. Pardo, (unknown), Tony Dhillon, Francesco Mauri, Heidi A. Lane, Nicholas R. Lemoine, Uwe Zangemeister‐Wittke, Michael J. Seckl, Alexandre Arcaro	79
8	Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in Apc ^Δ716 mice 2008 ·Proceedings of the National Academy of Sciences ·Teruaki Fujishita, Koji Aoki, Heidi A. Lane, Masahiro Aoki, Makoto M. Taketo	135
9	RET/PTC-Induced Cell Growth Is Mediated in Part by Epidermal Growth Factor Receptor (EGFR) Activation: Evidence for Molecular and Functional Interactions between RET and EGFR 2008 ·Cancer Research ·Michelle Croyle, Nagako Akeno, Jeffrey A. Knauf, Doriano Fabbro, Xu Chen, (unknown), Heidi A. Lane, James A. Fagin	73
10	The Ret Receptor Tyrosine Kinase Pathway Functionally Interacts with the ERα Pathway in Breast Cancer 2008 ·Cancer Research ·Anne Boulay, Madlaina Breuleux, Christine Stephan, (unknown), Cathrin Brisken, Maryse Fiche, Markus Wartmann, Michael Stumm, Heidi A. Lane, Nancy E. Hynes	92
11	Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors 2008 ·Molecular Cancer Therapeutics ·Gunnar Johansson, Yonatan Y. Mahller, Margaret H. Collins, Mi‐Ok Kim, Takahiro Nobukuni, John P. Perentesis, Timothy P. Cripe, Heidi A. Lane, Sara C. Kozma, George Thomas, Nancy Ratner	104
12	mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt breakdown → 2006 ·Cancer Research ·Kathryn O’Reilly, (unknown), Qing‐Bai She, David B. Solit, Gordon B. Mills, Debra L. Smith, Heidi A. Lane, Francesco Hofmann, Daniel J. Hicklin, Dale L. Ludwig, José Baselga, Neal Rosen	2037
13	Differential anti-vascular effects of mTOR or VEGFR pathway inhibition: A rational basis for combining RAD001 and PTK787/ZK222584 2005 ·Cancer Research ·Terence O’Reilly, Jeanette M. Wood, Amanda Littlewood-Evans, Anne Boulay, Christian Schnell, (unknown), (unknown), Georg Martiny‐Baron, Heidi A. Lane	9
14	ERBB receptors and cancer: the complexity of targeted inhibitors breakdown → 2005 ·Nature reviews. Cancer ·Nancy E. Hynes, Heidi A. Lane	2591
15	The mTOR pathway in estrogen response: A potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor Letrozole (Femara®) in breast carcinoma 2004 ·Cancer Research ·(unknown), Anne Boulay, Sabine Zumstein-Mecker, Dean B. Evans, Terence O’Reilly, Heidi A. Lane	23
16	The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. 2002 ·PubMed ·Andréa Barretto Motoyama, Nancy E. Hynes, Heidi A. Lane	206
17	Myc and Mammary Cancer: Myc is a Downstream Effector of the ErbB2 Receptor Tyrosine Kinase 2001 ·Journal of Mammary Gland Biology and Neoplasia ·Nancy E. Hynes, Heidi A. Lane	31
18	Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling 2001 ·Annals of Oncology ·Heidi A. Lane, Andréa Barretto Motoyama, Iwan Beuvink, Nancy E. Hynes	95
19	ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27 ^Kip1 -Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency 2000 ·Molecular and Cellular Biology ·Heidi A. Lane, Iwan Beuvink, Andréa Barretto Motoyama, J.M. Daly, Richard M. Neve, Nancy E. Hynes	253
20	On the Regulation and Function of Human Polo-like Kinase 1 (PLK1): Effects of Overexpression on Cell Cycle Progression 1997 ·Biochemical and Biophysical Research Communications ·Kirsten Mundt, Roy M. Golsteyn, Heidi A. Lane, Erich A. Nigg	167

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact